ObvioHealth

Executive Summary

ObvioHealth is a US-based digital health company offering ObvioGo®, an enterprise platform for hybrid and decentralized clinical trials. Founded in 2017 and headquartered in Orlando, the company provides tools for study design, eConsent, recruitment, virtual visits, and data capture, aiming to accelerate clinical research through improved efficiency and participant engagement. With the growing adoption of decentralized trial models post-pandemic, ObvioHealth is well-positioned to capture market share, particularly among biopharma sponsors seeking to reduce trial timelines and costs. The company's platform addresses key pain points in traditional trials, such as patient recruitment and retention, by enabling remote participation and streamlined operations. While specific financial details and valuation are not disclosed, ObvioHealth's focus on the rapidly expanding decentralized clinical trial market—expected to grow significantly in the coming years—suggests strong potential for revenue growth and strategic partnerships. The company's ability to differentiate through a comprehensive, end-to-end platform will be critical to its success against established competitors like Medidata and Science 37.

Upcoming Catalysts (preview)

• H2 2026Series B or C Funding Round70% success
• H1 2026Major Pharma Partnership or Contract Win60% success
• 2026Regulatory Endorsement or FDA Guidance Inclusion50% success